Unidad de Coloproctología del HUGetafe

Unidad de Coloproctología del Hospital Universitario de Getafe. #HospitaldeGetafe

[Unidad de Coloproctología del HUGetafe @ColonGetafe]

Nuestros mejores deseos para este 2026 🎄.

[Revista Española de Anestesiología y Reanimación @_REDAR_]

Qué importante es la optimización perioperatoria de los pacientes‼️
Seguro que conoces la Vía RICA... Sabes que hay actualización recién salida del horno❓
La puedes leer aquí 😊
👇🏼👇🏼👇🏼
https://t.co/FWNvPloi6m

[Unidad de Coloproctología del HUGetafe @ColonGetafe]

DEP

[Paulo G. Kotze @pakotze]

O Globo: Morre Angelita Gama, médica pioneira da coloproctologia no Brasil e referência mundial no tratamento do câncer de reto, aos 94 anos https://t.co/0BtBHXNhHx

[Unidad de Coloproctología del HUGetafe @ColonGetafe]

Updates on Management of Anal Cancer: A New Era Has Begun | American Society of Clinical Oncology Educational Book
🟢Free Access
https://t.co/IyPUAvzKYv

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

🆕 Research | Adjuvant chemoradiotherapy versus completion total mesorectal excision after local excision for early rectal cancer (TESAR): a multicentre, randomised, controlled, phase 3, non-inferiority trial

https://t.co/aBfWfRHOg6

#OncTwitter #GITwitter #rectalcancer

[Unidad de Coloproctología del HUGetafe @ColonGetafe]

Jueves 4 junio.

[Dr. Hussein Faour @drhusseinfaour]

This is a thoughtful and optimistic overview of emerging surgical techniques for ileocolic Crohn’s disease. You do a great job framing the practical realities (surgery isn’t curative, bowel preservation is critical, and recurrence remains a major challenge) while highlighting two promising mesenteric-targeted approaches without overhyping them.
Regarding mesenteric excision, the idea that the mesentery isn’t just passive scaffolding but can act as an inflammatory reservoir makes a lot of biological sense. Extending the mesenteric resection (similar to oncologic principles) is a logical evolution, though it requires careful technique to avoid vascular or autonomic issues.

[AECP @AECP_FAECP]

Feliz lunes a todos! Después de la resaca del #AECP2026 de Toledo, hoy
caso clínico rápido.
💁‍♀️ 49 años, multipara y fístula transesfinteriana anterior baja. Continencia correcta. No lesiones esfinterianas previas. Muy sintomática.
¿Qué tratamiento ofreces?

[Carlos Cerdán @DrCarlosCerdan]

@ColonGetafe @GermFTsurgery @prehab4cancer @me4_so @SoMe4SurgeryPr1 @SocGerMadrid @FISIOSEPAR @coloproctoaec @AECP_FAECP @CirujanosMad @ContraCancerEs https://t.co/rqaC5Z714a
Aquí tenéis toda la info y el enlace para inscripción. ¡¡¡No lo dejéis que vuelan!!!

[Unidad de Coloproctología del HUGetafe @ColonGetafe]

🟢Te lo puedes descargar gratis.

[Sociedad Española de Patología Digestiva (SEPD) @sepdigestiva]

Si aún no lo has hecho, te invitamos a leer el Libro Blanco sobre Cribado Poblacional del #Cáncer #Colorrectal (CCR) en España. Promovido y coordinado por @sepdigestiva, describe la situación de programas poblacionales de cribado CCR españoles, realiza un análisis estratégico y establece recomendaciones.
Acceder desde aquí https://t.co/s9vIPVINwH

[@ACPGBI @ACPGBI]

🚨 Don’t miss the prestigious @Dukes_Club Lecture #ACPGBI2026 with Prof George Chang on
🩺 “Advanced Rectal Cancer”
Chaired by@ioannadrami (Dukes’ Club President)
A key session for anyone involved in colorectal surgery & oncology
🎟️ Register now: https://t.co/6mgocqB7S8

[Unidad de Coloproctología del HUGetafe @ColonGetafe]

@DrCarlosCerdan @GermFTsurgery @prehab4cancer @me4_so @SoMe4SurgeryPr1 @SocGerMadrid @FISIOSEPAR @coloproctoaec @AECP_FAECP @CirujanosMad @ContraCancerEs Donde nos inscribimos?

[AIS Medical Network. @AISMedicalNet]

Tomorrow. Dr @AnaOtero_MD demonstrates robotic LAR and mesorectal dissection. The session covers systematic landmarks from docking to ICG perfusion assessment. Educational video available May 20. https://t.co/voXRLb0nnd #Surgery #MedEd

[Techniques in Coloproctology Journal @TechColoproctol]

Join us for a FREE TCOL virtual session! Sign up here --> https://t.co/RwxZeGsFUs
On 9 June our EIC Dr Perez and AE Dr McKechnie will host coauthors Dr Meyer and Dr Douissard for the presentation and discussion of their TCOL article "Fascial closure techniques at stoma reversal"

[DCRjournal @DCRjournal]

Practice Pearls this month with a clarification of the concepts of total and tailored mesorectal excision for rectal cancer by Drs Moran, Laurberg & Heald. Read more in this month's #DCRJournal: https://t.co/sMhvTXmavE

[Frontline Gastro @FrontGastro_BMJ]

Getting to the bottom of perianal Crohn’s disease 🍑🔎

In @FrontGastro_BMJ, this practical review brings together essential insights into perianal Crohn’s disease — from recognising disease phenotype to multidisciplinary assessment, medical therapy and surgical collaboration. 🧑‍⚕️🤝

A must-read for IBD teams managing one of the most complex and life-altering Crohn’s phenotypes.

Read more: https://t.co/AgWAJcE1so

#PerianalCrohns #CrohnsDisease #IBD #Fistula #IBDSurgery #FrontlineGastro #GItwitter #InflammatoryBowelDisease #IBDTreatment #ColorectalSurgery @eathar_s @easan_anand @TheoHPelly @Shivani_gargi15 @philtozer1 @DrAilsaHart @BritSocGastro @my_UEG @AmCollegeGastro @DDWMeeting @ESGE_news @dr_aditi_kumar @OTavabie @DrJMKennedy @DunnePdj @TrevorTabone @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman

[Nagendran Balaramal @NagendranBR]

Joint ESTRO - ESR talk on rectal cancer. My take-away: Anatomy remains core for treatment selection. However focus should also be on predicted biology, response, preservation of function and quality of life. @GI_RadOnc @OncoAlert
#ESTRO26 @estro

[Unidad de Coloproctología del HUGetafe @ColonGetafe]

Locally advanced rectal cancer: what patients and practitioners should know about non-operative management - eClinicalMedicine https://t.co/CSrbQwE0Js

[DCRjournal @DCRjournal]

This month's Resident Corner focuses on Shared Decision-Making in Locally Advanced Rectal Cancer. Read now in #DCRJournal: https://t.co/c4BRMU1gjR

[DCRjournal @DCRjournal]

Response to the Letter to the Editor "Organ Preservation in Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy With Endoscopic Submucosal Dissection" Read the authors' response now in #DCRJournal: https://t.co/hJbD0gwI9H

[Dr. Nina Niu Sanford @NiuSanford]

This is a great read on watch & wait in rectal cancer.

B/c patients with local regrowth after WW have higher rates of distant mets, there has been an intuitive fear that regrowth is causal (i.e delaying TME permits metastatic seeding hence WW risky).

The authors here argue (and I agree) that regrowth/metastases are manifestations of intrinsic aggressive tumor biology because:

1) no difference in time to surgery in patients w pCR/regrowth who developed mets vs. those who didn't (if delay were causal, would expect longer delay in patients who developed M1).

2) in OPRA secondary analysis, patients with cCR underwent least surgery/longest observation while those with incomplete response had surgery most frequently/immediately. But outcomes still tracked with response phenotype not timing of surgery (i.e. cCR did best).

3) tumor response itself is prognostic (i.e. even when all pts undergo TME, more regression after neoadjuvant therapy --> better DFS/DM).

4) modern tumor evolution data suggest metastatic spread mostly happens early.

5) chemo/radioresistance appears to be linked to metastatic potential (i.e. regrowth is a marker of aggressive biology not the mechanism itself).

IMO a persuasive argument against hypothesis that regrowth seeds metastasis, but rather biology=dominant driver. @OncoAlert